Nitroxyl (HNO) as a vasoprotective signaling molecule.

  title={Nitroxyl (HNO) as a vasoprotective signaling molecule.},
  author={Michelle L. Bullen and Alyson Anne Miller and Karen L. Andrews and Jennifer C. Irvine and Rebecca Helen Ritchie and Christopher G. Sobey and Barbara K Kemp-Harper},
  journal={Antioxidants \& redox signaling},
  volume={14 9},
Nitroxyl (HNO), the one electron reduced and protonated form of nitric oxide (NO(•)), is rapidly emerging as a novel nitrogen oxide with distinct pharmacology and therapeutic advantages over its redox sibling. Whilst the cardioprotective effects of HNO in heart failure have been established, it is apparent that HNO may also confer a number of vasoprotective properties. Like NO(•), HNO induces vasodilatation, inhibits platelet aggregation, and limits vascular smooth muscle cell proliferation. In… 

HNO/Thiol Biology as a Therapeutic Target

This book chapter summarizes all recent advancements in the field of HNO (bio)chemistry and pharmacology.

Nitroxyl (HNO): a novel redox signaling molecule.

The present Forum issue summarizes the intriguing chemistry and biology of HNO and highlights its impact in the cardiovascular and central nervous systems and suggests the development of sensitive methods for HNO detection in a biological system is needed to conclusively prove its in vivo generation.

Induction of caveolin-3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy

Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes

HNO and NO· contribute to the NO synthase (NOS)-sensitive component of endothelium-dependent relaxation in mesenteric and femoral arteries and are sustained in diabetes.

Nitroxyl (HNO) reduces endothelial and monocyte activation and promotes M2 macrophage polarization.

The data demonstrate that HNO donors can reduce factors that are associated with and which precede atherosclerosis and may thus be useful therapeutically and since the effects of the HNO donor were not subject to tolerance, this confers an additional advantage over NO donors.

Nitroxyl (HNO) as a potential theranostic in the cancer arena.

The experimental evidence suggests the therapeutic potential of HNO in tumor pharmacology, such as neuroblastoma, gastrointestinal tumor, ovarian, lung and breast cancers, and HNO donors have been demonstrated to attenuate tumor proliferation and angiogenesis.

Nitroxyl (HNO) suppresses vascular Nox2 oxidase activity.

Nitroxyl (HNO) Stimulates Soluble Guanylyl Cyclase to Suppress Cardiomyocyte Hypertrophy and Superoxide Generation

It is demonstrated that HNO prevents cardiomyocyte hypertrophy, and that cGMP-dependent NADPH oxidase suppression contributes to these antihypertrophic actions.

Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function.

New features of HNO's cardiovascular effects that when combined with its positive inotropic/lusitropic action may render HNO donors an attractive addition to the current therapeutic armamentarium for treating patients with acutely decompensated congestive heart failure are reviewed.

NO and HNO donors, nitrones, and nitroxides: Past, present, and future

Recent advances in the chemistry of NO and HNO donors, nitrones, and nitroxides are reviewed and its pharmacological significance and potential therapeutic application are discussed.



Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms.

It is concluded that HNO causes vasorelaxation via a cGMP-dependent activation of K(v) channels and that there are different profiles of vasore laxant activity for the redox siblings HNO and NO(.).

A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Investigation of mechanisms underlying HNO-mediated vasodilatation in phenylephrine pre-constricted pressurized mesenteric arteries and on membrane currents in isolated smooth muscle cells suggests a physiological role in vasodILatation through the vasculature.

The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor.

The results indicate that HNO is capable of eliciting vasorelaxation in both rabbit aorta and bovine intrapulmonary artery by a guanylate cyclase-dependent pathway.

Nitroxyl Anion Donor, Angeli’s Salt, Does Not Develop Tolerance in Rat Isolated Aortae

Vascular tolerance does not develop to HNO, nor does cross-tolerance between HNO and GTN occur, and HNO donors may have therapeutic advantages over traditional nitrovasodilators.

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.

It is shown in vivo that oxidative stress and related vascular disease states, including human diabetes mellitus, led to an sGC that was indistinguishable from the in vitro oxidized/heme-free enzyme, and BAY 58-2667 was more effective and potentiated under pathophysiological and oxidative stress conditions.

Antioxidant actions of nitroxyl (HNO).

Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm.

This article discusses the emerging aspects of HNO chemistry and attempts to provide a framework for the distinct effects of NO and HNO in vivo, providing an interesting redox system.

Mechanisms Underlying Activation of Soluble Guanylate Cyclase by the Nitroxyl Donor Angeli's Salt

Data indicate that Angeli's salt activates sGC exclusively via NO, formed either via SOD-catalyzed oxidation of HNO or through a minor AS decomposition pathway that is unmasked in the presence of H NO scavenging thiols.